Cite
1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
MLA
Stanislas Pol, et al. “1415 Confirmation That Quadruple Therapy with Daclatasvir (Ns5a Inhibitor), Asunaprevir (Ns3 Inhibitor) and Peginterferon/Ribavirin Results in High Rate of Svr4 in Hcv Genotype 1 Null Responders.” Journal of Hepatology, vol. 56, Apr. 2012, p. S557. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........23cd2b6437dd83f8fa258950f61630c1&authtype=sso&custid=ns315887.
APA
Stanislas Pol, Anna S.F. Lok, Christophe Hézode, Claudio Pasquinelli, Lawrence Serfaty, Megan Wind-Rotolo, Timothy Eley, G.T. Everson, Fiona McPhee, M. Bourlière, Shu-Pang Huang, David F. Gardiner, E.J. Lawitz, Patrick Marcellin, Dennis M. Grasela, & Maribel Rodriguez-Torres. (2012). 1415 Confirmation That Quadruple Therapy with Daclatasvir (Ns5a Inhibitor), Asunaprevir (Ns3 Inhibitor) and Peginterferon/Ribavirin Results in High Rate of Svr4 in Hcv Genotype 1 Null Responders. Journal of Hepatology, 56, S557.
Chicago
Stanislas Pol, Anna S.F. Lok, Christophe Hézode, Claudio Pasquinelli, Lawrence Serfaty, Megan Wind-Rotolo, Timothy Eley, et al. 2012. “1415 Confirmation That Quadruple Therapy with Daclatasvir (Ns5a Inhibitor), Asunaprevir (Ns3 Inhibitor) and Peginterferon/Ribavirin Results in High Rate of Svr4 in Hcv Genotype 1 Null Responders.” Journal of Hepatology 56 (April): S557. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........23cd2b6437dd83f8fa258950f61630c1&authtype=sso&custid=ns315887.